What are your top takeaways from SABCS 2023?
4 Answers
Mednet MemberInvited Expert
Radiation Oncology · The University of Texas MD Anderson Cancer Center
Answered on
- The B51 trial surprised the radiation oncology community, showing that in patients with an exceptional response to systemic therapy, radiation to the regional nodes did not result in a significant improvement in the invasive breast cancer recurrence free interval nor the isolated loco-regional recu...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on
- INAVO120 study: The study looked at triplet therapy using inavolisib (PIK3CA inhibitor) plus palbociclib and fulvestrant vs. palbociclib and fulvestrant in women with metastatic ER+HER2- breast cancer that has recurred while on or within 12 months of adjuvant endocrine therapy. The progression free...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Washington University School of Medicine
Answered on
- GS03-13: Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis. The progression free survival improvement from adding i...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on
- Updated analysis of the KATHERINE trial at a median follow up of 8.4 years that continues to show clinically and statistically significant benefits of adjuvant TDM1 as compared to trastuzumab in women with HER2-positive breast cancer who have residual disease after neo-adjuvant chemotherapy. The up...
Join for free or sign in to see the full answer